- Home
- STEM vs VTVT Comparison
STEM vs VTVT Comparison
Compare STEM & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STEM | VTVT |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.9M | 127.0M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | STEM | VTVT |
|---|---|---|
| Price | $16.15 | $37.91 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | $14.60 | ★ $43.50 |
| AVG Volume (30 Days) | ★ 183.7K | 12.1K |
| Earning Date | 10-29-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $164,948,000.00 | $17,000.00 |
| Revenue This Year | $3.43 | N/A |
| Revenue Next Year | $12.04 | N/A |
| P/E Ratio | $1.31 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.81 | $13.15 |
| 52 Week High | $33.60 | $38.46 |
Technical Indicators
Market Signals| Indicator | STEM | VTVT |
|---|---|---|
| Relative Strength Index (RSI) | 44.10 | 70.72 |
| Support Level | $15.92 | $33.75 |
| Resistance Level | $17.61 | $38.46 |
| Average True Range (ATR) | 1.63 | 2.30 |
| MACD | -0.15 | 0.30 |
| Stochastic Oscillator | 7.35 | 88.99 |
Price Performance
Historical ComparisonAbout STEM Stem Inc.
Stem Inc is a provider of energy storage systems. The company bundles third-party hardware with its proprietary Athena software to provide customers a turnkey solution. Stem sells its solutions to commercial and industrial customers as well as independent power producers and renewable developers. Its solutions help customers maximize renewable energy generation and help build a cleaner and more resilient grid. The Company operates as one operating segment that is focused exclusively on technology services that transform the way energy is distributed and consumed.
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential novel first-in-class oral liver-selective glucokinase activator being investigated for the treatment of type 1 diabetes. The group and its development partners are investigating multiple molecules across different indications for chronic diseases. Its product pipeline are HPP737, Azeliragon, TTP-RA, TTP273, HPP971 / HPP3033, and HPP593.